Eli Lilly Dives As Zepbound Takes A Back Seat To Novo Nordisk's Wegovy At CVS
Eli Lilly topped expectations Thursday, but shares tumbled after CVS selected Novo Nordisk's Wegovy as its preferred weight-loss drug. The post Eli Lilly Dives As Zepbound Takes A Back Seat To Novo Nordisk's Wegovy At CVS appeared first on Investor's Business Daily.
Eli Lilly topped expectations Thursday, but shares tumbled after CVS selected Novo Nordisk's Wegovy as its preferred weight-loss drug.
The post Eli Lilly Dives As Zepbound Takes A Back Seat To Novo Nordisk's Wegovy At CVS appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
